Author:
Kuzmanović Adrian,Lin Cheng,Bartneck Matthias
Publisher
Springer Nature Switzerland
Reference129 articles.
1. Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15:387–404
2. Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M (2021) MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14:1–49
3. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH, Karsh LI (2015) Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer 3:1–13
4. Ananthakrishnan A, Gogineni V, Saeian K (2006) Epidemiology of primary and secondary liver cancers. In: Seminars in interventional radiology. Copyright© 2006 by Thieme Medical Publishers, New York
5. Aurisicchio L, Pallocca M, Ciliberto G, Palombo F (2018) The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res 37:1–10